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Treatment of multidrug-resistant Pseudomonas aeruginosa
and Acinetobacter baumannii pneumoniaDear Editor,
The problem of multidrug-resistant (sensitive only to
polymyxins) Pseudomonas aeruginosa and Acinetobacter
baumannii infections has been increasing with alarming
rates worldwide in patients with or without cystic fibrosis.
Among various sites of infection due to these pathogens,
pneumonia is one of special interest because of its incidence
and problems related to pharmacokinetic and pharmacody-
namic parameters. A recent experimental study regarding A.
baumannii pneumonia models in mice highlighted further
the difficulties in the treatment of this infection [1]. We
would like to make a few comments on this important
clinical problem based on our clinical experience with the
management of multidrug-resistant (MDR) P. aeruginosa
and A. baumannii pneumonia.
We have recent experience with 93 patients without
cystic fibrosis who received treatment with intravenous
colistin, for more than 72 h, for infections due to MDR
Gram-negative bacteria (P. aeruginosa and A. baumannii)
[2]. Forty-five of these received intravenous colistin for the
treatment of nosocomial pneumonia and 48 for infections
due to Gram-negative bacteria in other body sites,
including bacteremia. The observed clinical cure in
patients with nosocomial pneumonia compared to patients
with infection in other body sites was the same: 30 /45
(66.7%) vs. 32 /48 (66.7%) ( p =1.0). Also, survival was
not different between the two groups: 34 /45 (75.6%) vs
33 /48 (69%) ( p =0.47). In the majority of our patients
intravenous colistin was concurrently administered with
other antibiotics with spectrum against Gram-negative
bacteria, namely meropenem, imipenem, ampicillin/sulbac-
tam, piperacillin/clavulanic acid, ceftazidime, ciprofloxa-
cin, or gentamicin. Similar results were noted in a recent
study from Spain that compared the effectiveness of
intravenous colistin with that of intravenous imipenem
for the treatment of MDR A. baumannii ventilator-
associated pneumonia (VAP); clinical cure, in-hospital
mortality, and VAP-related mortality were not different in
the groups of patients treated with intravenous colistin or
imipenem [3].1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.02.003A subset of our patients with MDR Gram-negative
pneumonia also received aerosolized colistin as an adjunc-
tive to the intravenous treatment [4]. The mean daily dosage
of aerosolized colistin was 3.2 million IU (256 mg), divided
in 3 equal doses administered every 8 h. The survival and
clinical cure of the infection was better, although without
statistical significance, in patients with pneumonia who
received aerosolized and intravenous colistin compared to
patients who received only intravenous colistin [clinical
cure: 7 /8 patients (87.5%) vs. 30 /45 patients (66.7%),
p =0.67, survival: 7 /8 patients (87.5%) vs. 34 /45 patients
(75.6%), p=0.41].
Possible explanations for the reported poor results
obtained from the use of colistin as monotherapy for
pneumonia are difficult to be assumed, since there are
limited pharmacokinetic/pharmacodynamic data regarding
this medication. Old reports suggested that colistin is poorly
distributed to pleural cavity and lung parenchyma, as well as
to some other tissues, mainly due to its large molecular size
and not due to protein binding. However, there are no
enough available data to fully support these suggestions. A
recent study determined the pharmacokinetics of intra-
venous and aerosolised colistin administered for the
management of acute pulmonary infections in patients with
cystic fibrosis [5]. Sputum sampling revealed colistin
concentrations that markedly exceeded the observed plasma
concentrations.
The role of colistin, if any, as monotherapy for the
management of pneumonia due to Gram-negative bacteria
needs further clarification. However, the combination of
aerosolised and intravenous colistin may be a useful
therapeutic option for the management of pneumonia due
to Gram-negative bacteria, because it may achieve better
concentrations of the medication in lung parenchyma.References
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